Filing Flows › Elite Pharmaceuticals (ELTP) › R&D spending
Elite Pharmaceuticals (ELTP) R&D spending by quarter
Elite Pharmaceuticals' R&D spending was $2.0M in Q1 FY27 (first quarter fiscal 2027), +24% from Q4 FY26. Over the last 7 quarters it ranged from $1.0M (Q3 FY26) to $2.0M (Q4 FY25).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q1 FY27 | $2.0M | +24% | +21% |
| Q4 FY26 | $1.6M | +58% | -20% |
| Q3 FY26 | $1.0M | -25% | -42% |
| Q2 FY26 | $1.4M | -17% | — |
| Q1 FY26 | $1.7M | -18% | — |
| Q4 FY25 | $2.0M | +14% | — |
| Q3 FY25 | $1.8M | — | — |
Q1 FY27 at a glance
Elite Pharmaceuticals, Q1 FY27: revenue $32.4M (-20% year over year), operating margin 23.3%, net earnings $5.9M, operating cash flow $10.1M. The chart follows the revenue to costs, profit and cash.
Questions
What is Elite Pharmaceuticals' R&D spending?
Elite Pharmaceuticals' R&D spending was $2.0M in Q1 FY27 (first quarter fiscal 2027), +24% from Q4 FY26.
How has Elite Pharmaceuticals' R&D spending changed?
Over the last 7 quarters it ranged from $1.0M (Q3 FY26) to $2.0M (Q4 FY25).